It may be of interest to apply CRSO to established subtypes of TCGA cancer types such as melanomas that are wild type for both BRAF and NRAS or basal‐like breast cancers, which have limited treatment options and poor prognosis (Bernard et al,2009; Cancer Genome Atlas Network, 2012). Here, BRAF is linked to melanoma.